Biogen Inc. (NASDAQ:BIIB), a $20.8 billion ... the United States and Europe are now reviewing a higher dose regimen of nusinersen, a drug designed to treat spinal muscular atrophy (SMA).

Biogen (BIIB) announced that the U.S. Food ... has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy, SMA. The higher dose regimen of nusinersen ...

and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

Simultaneously, Biogen is under review by the FDA and EMA for a higher dose regimen of the same SMA drug, nusinersen. The company has maintained a positive outlook with an Outperform rating from ...

Biogen has made a further push into RNA-based ... the neurological disorder spinal muscular atrophy (SMA) – Spinraza (nusinersen) – is one result of that effort. The antisense oligonucleotide ...

Royalty also holds rights on Biogen’s MS medication Tysabri (natalizumab) and spinal muscular atrophy drug Spinraza (nusinersen), acquired through agreements with Ionis and Perrigo. The deal ...

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...

which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq ...